Non-Invasive Biomarkers in Prostate Cancer Disease Management

Inclusion Criteria

• * RETROPECTIVE/PROSPECTIVE COLLECTION: ** Prostate cancer patients who had received primary diagnosis at Moffitt or outside the cancer center with available records (radiology, pathology, access to samples). No-surgery (Intermediate risk) group: patients diagnosed with pre-biopsy mpMRI, blood plasma: the biopsy must consist of a pathological diagnosis with a Gleason pattern score ** Surgery (high risk) group: patients who had radical prostatectomy (RP) with (or with-out) mpMR imaging, bio fluids available for research will be accrued for this group. We follow the NCCN recommendations for high-risk groups inclusion and follow-up criteria * Treatment group: patients with pre and post-treatment for prostate cancer with/without MR imaging, bio-fluids (blood, urine) available for research ** Serum PSA (for Intermediate disease) >= 4 ng/ml and =< 20 ng/ml and PSA >= 10 ng/ml (for late disease), within 3 months of study enrollment ** Age >= 35 and =< 85 years ** Zubrod/ECOG performance status < 2 ** Ability to understand and willingness to sign a written informed consent document ** Patients who agree to have a multiparametric MRI with targeted/template biopsy ** Patients must agree to fill out the longitudinal psychosocial questionnaires assessing health related quality of life ** Availability of bio-samples (blood plasma, urine) for exosomal, proteomic, genomic and pathology (H&E slides, IHC slides) ** Quantity of bio-samples; blood, urine, tissue sections (including FFPE) for each region of interest * COLLABORATIVE SITES: ** Patients' inclusion criteria will follow primary site description (Moffitt), accrual at collaborating site, and patients with mpMR imaging at baseline and follow up. Available primary clinical patient demographics (age, race, ethnicity, etc), primary diagnosis, and others ** Patients will have un-stained tissue sections for research (up to 4 sections) at the regions identified by the oncologist. Pathological specimens (H&E sections and blocks) and digitized sections are available for research ** Patients will have blood plasma (or fresh blood), urine, tissue specimens for research ** Standard of care reports that includes the oncologist, radiologist/pathologist, diagnostic imaging scans (mpMRI/PSMA-PET/ultrasound etc) ** Follow up clinical records available for research

Exclusion Criteria

• * The subject is not a candidate for multiparametric MRI with contrast. Some reasons may include (but are not limited to): renal insufficiency, foreign body or pacemakers * No prior pelvic radiotherapy * No prior surgery to the prostate, other than transurethral procedures for benign prostatic hyperplasia (e.g., transurethral resection, green light laser treatment) * No concurrent, active malignancy, other than non-metastatic skin cancer of any type, superficial bladder cancer, or early-stage chronic lymphocytic leukemia (well-differentiated small cell lymphocytic lymphoma) or < stage IV follicular lymphoma. If a prior malignancy is in remission for >= 3 years, then the patient is eligible * Bilateral hip replacement